Home LiteratureArticle Details
PMID: 25678021 Published · ppublish English Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).

Hepatology (Baltimore, Md.) ·Vol. 62 ·No. 3 ·2015-09-00 ·Pages 737-50

Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S, ANRS CO12 CirVir Group

Abstract

Various critical events, liver related or not, occur in patients with compensated cirrhosis, but their respective burden remains to be prospectively assessed. The aim of this prospective cohort study involving 35 French centers was to capture the whole spectrum of complications occurring in compensated viral cirrhosis (VC) using competing risks analyses. Inclusion criteria were: histologically proven cirrhosis resulting from hepatitis C virus (HCV) or hepatitis B virus (HBV); Child-Pugh A; and no previous hepatic complications. The cohort was considered as a multistate disease model, cumulative incidences (CumIs) of events were estimated in a competing risks framework. A total of 1,654 patients were enrolled from 2006 to 2012 (HCV, 1,308; HBV, 315; HCV-HBV, 31). During a median follow-up of 34 months, at least one liver nodule was detected in 271 patients, confirmed as hepatocellular carcinoma (HCC) in 128 (4-year cumI: 10.5%) and cholangiocarcinoma in 3. HCC incidence was higher in HCV (4-year cumI: 11.4% vs. 7.4%; P = 0.05). HCC fulfilled Milan criteria in 79.3%, leading to curative treatment in 70.4%. Liver decompensation occurred more frequently in HCV patients (4-year cumI: 10.8% vs. 3.6%; P = 0.0004). Virological eradication/control was achieved in 34.1% of HCV and 88.6% of HBV patients and was associated with a marked decrease in HCC, decompensation, and bacterial infection incidences. Survival was shorter in HCV patients (4-year cumI: 91.6% vs. 97.2%; P = 0.0002). Death (n = 102; missing data: 6) was attributed to liver disease in 48 (47%; liver cancer: n = 18; miscellaneous, n = 30) and extrahepatic causes in 48 (47%; bacterial infection: n = 13; extrahepatic cancers: n = 10; cardiovascular events: n = 5; miscellaneous, n = 20). After 3 years of follow-up, extrahepatic events still explained half of deaths in patients with compensated VC. A strong decrease in complications was linked to virological eradication/control.

MeSH Terms
Adult Analysis of Variance Carcinoma, Hepatocellular/mortality,physiopathology,virology Cause of Death Cohort Studies Disease Progression Female France Hepatitis B/complications,pathology Hepatitis C/complications,pathology Humans Liver Cirrhosis/complications,mortality,virology Liver Failure/mortality,pathology,virology Liver Neoplasms/mortality,pathology,virology Longitudinal Studies Male Middle Aged Multivariate Analysis Predictive Value of Tests Proportional Hazards Models Prospective Studies Risk Assessment Survival Analysis
Authors & Affiliations
42 authors, click to expand affiliations / ORCID
Trinchet Jean-Claude
AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy, Université Paris 13, Bobigny et INSERM U1162, Université Paris 5, Paris, France.
Bourcier Valérie
AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy, Université Paris 13, Bobigny et INSERM U1162, Université Paris 5, Paris, France.
Chaffaut Cendrine
AP-HP, Hôpital Saint-Louis, SBIM, Université Paris Diderot, Inserm UMR 1153, Paris, France.
Ait Ahmed Mohand
AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy, Université Paris 13, Bobigny et INSERM U1162, Université Paris 5, Paris, France.
Allam Setty
ANRS (Agence Nationale de Recherche sur le SIDA et les hépatites virales), Paris, France.
Marcellin Patrick
AP-HP, Hôpital Beaujon, Service d'Hépatologie, Clichy, France.
Guyader Dominique
CHU Pontchaillou, Service d'Hépatologie, Rennes, France.
Pol Stanislas
AP-HP, Hôpital Cochin, Département d'Hépatologie et INSERM U1016, Université Paris Descartes, Paris, France.
Larrey Dominique
Hôpital Saint Eloi, Service d'Hépatologie, Montpellier, France.
De Lédinghen Victor
Hôpital Haut-lévêque, Service d'Hépatologie, Bordeaux, France.
Ouzan Denis
Institut Arnaud Tzanck, Service d'Hépatologie, St Laurent du Var, France.
Zoulim Fabien
Hôpital Hôtel Dieu, Service d'Hépatologie, Lyon, France.
Roulot Dominique
AP-HP, Hôpital Avicenne, Service d'Hépatologie, Bobigny, France.
Tran Albert
CHU de Nice, Service d'Hépatologie, et INSERM U1065, Université de Nice-Sophia-Antipolis, Nice, France.
Bronowicki Jean-Pierre
Hôpital Brabois, Service d'Hépatologie, Vandoeuvre-les-Nancy, France.
Zarski Jean-Pierre
Hôpital Michallon, Service d'Hépatologie, Grenoble, France.
Goria Odile
Hôpital Charles-Nicolle, Service d'Hépatologie, Rouen, France.
Calès Paul
CHU d'Angers, Service d'Hépatologie, Angers, France.
Péron Jean-Marie
Hôpital Purpan, Service d'Hépatologie, Toulouse, France.
Alric Laurent
CHU Toulouse, Service de Médecine Interne-Pôle Digestif UMR 152, Toulouse, France.
Bourlière Marc
Hôpital Saint Joseph, Service d'Hépatologie, Marseille, France.
Mathurin Philippe
Hôpital Claude Huriez, Service d'Hépatologie, Lille, France.
Blanc Jean-Frédéric
Hôpital St André, Service d'Hépatologie, Bordeaux, France.
Abergel Armand
Hôpital Hôtel Dieu, Service d'Hépatologie, Clermont-Ferrand, France.
Serfaty Lawrence
AP-HP, Hôpital Saint-Antoine, Service d'Hépatologie, Paris, France.
Mallat Ariane
AP-HP, Hôpital Henri Mondor, Service d'Hépatologie, Créteil, France.
Grangé Jean-Didier
AP-HP, Hôpital Tenon, Service d'Hépatologie, Paris, France.
Buffet Catherine
AP-HP, CHU Kremlin-Bicêtre, Service d'Hépatologie, Le Kremlin-Bicêtre, France.
Bacq Yannick
Hôpital Trousseau, Service d'Hépatologie, Tours, France.
Wartelle Claire
Hôpital d'Aix-En-Provence, Service d'Hépatologie, Aix-En-Provence, France.
Dao Thông
Hôpital de la Côte de Nacre, Service d'Hépatologie, Caen, France.
Benhamou Yves
AP-HP, Groupe Hospitalier de La Pitié-Salpêtrière, Service d'Hépatologie, Paris, France.
Pilette Christophe
CHU Le Mans, Service d'Hépatologie, Le Mans, France.
Silvain Christine
CHU de Poitiers, Service d'Hépatologie, Poitiers, France.
Christidis Christos
Institut Mutualiste Montsouris, Service d'Hépatologie, Paris, France.
Capron Dominique
Hôpital Amiens Nord, Service d'Hépatologie, Amiens, France.
Thiefin Gérard
Hôpital Robert Debré, Service d'Hépatologie, Reims, France.
Hillaire Sophie
Hôpital Foch, Service d'Hépatologie, Suresnes, France.
Di Martino Vincent
Hôpital Jean Minjoz, Service d'Hépatologie, Besançon, France.
Nahon Pierre
AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy, Université Paris 13, Bobigny et INSERM U1162, Université Paris 5, Paris, France.
Chevret Sylvie
AP-HP, Hôpital Saint-Louis, SBIM, Université Paris Diderot, Inserm UMR 1153, Paris, France.
ANRS CO12 CirVir Group
Article Info
Journal
Hepatology (Baltimore, Md.)
Abbr.
Hepatology
ISSN
1527-3350
Published
2015-09-00
Epub
2015-00-20
Pages
737-50
Language
English
Region
United States
NLM ID
8302946
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]